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1106-120 lmmunomodulatory Effects of Growth Hormone 
Administration Are Associated With Improvement in 
Myocardial Contractile Performance in Dilated 
Cardiomyopathy Patients 
Stamatis Adamopoulos, John T. Par&is, John Paraskevaidis, Dimitrios Karatzas. 
Christos Krouois. Eftimios Livanls. Georoe Karavokas. Dlmitrios T. Kremastinos. Onassis 
Cardiac Surgery Center, Athens, Greece, Amalia Fleming Hospital, Athens, Greece 
Objectives: ‘Ib study the immunomodulatory effects of growth hormone (GH) and to 
investigate whether these effects are associated with the improvement of left ventricular 
(LV) contract& performance in dilated cardiomyopathy (DC) patients (pts). 
Background: Recent studies indicate that an abnormal immune response contributes to 
the progression of chronic heart failure (CHF). 
Methods: Plasma inflammatory cyiokines TNFa. IL-6, GM-CSF, its soluble receptor 
sGM-CSFR and MCP-I, soluble adhesion molecules slCAM-1 and sVCAM-I, and anti- 
inflammatory cytokines IL-10 and TGF-P were measured (EL&A) in 12 DC pts (NYHA III; 
LVEF:24+3%) before and after a 3-month subcutaneous administration of GH 4lU every 
other day (randomized crossover design). Peak oxygen uptake (VO2 max). end-systolic 
wall stress (ESWS), mean velocity of circumferential fiber shortening (Vdc) and contrac- 
tile reserve (change of VcfclESWS after dobutamine infusion) were also determined. 
Resulte: GH produced a significant reduction in plasma TNFa (7.6kl.l vs 5.4kO.9 pg/ 
ml, pcO.Ol), IL-6 (5.6*0.5 vs 4X+0.3 pgiml, p<O.O5), GM-CSF (27*2 vs 23+2 pgiml, 
p<O.O5), sGM-CSFR (4.OkO.4 vs 3.210.3 ng/ml, ~~0.05). MCP-1 (199*5 vs 182*6 pg/ml, 
p<O.O5), slCAM-1 (324+33 vs 274*27 ng/ml, ~~0.05) and #/CAM-l (1237&6 vs 
1043+77 nglml, pc0 05), a?. well as a significant increase in ratio IL-lO/TNF-a (1.9kO.3 vs 
3.5+0.9, pcO.O5), IL-IO/IL-6 (2.620.6 “s 3.2tO.5, ~~0.05) and TGF-P/TNFa (3.1kO.6 “s 
4 4eO.6, p=O 05) in DC pts A significant reduction of ESWS (840+43 vs 634*41 gr/cm’. 
p<O.O05), and a significant increase of contractile reserve (0.0003~0.0001 vs 
0.0005~0.0001 circ’cr&gr’sec. p<O.OOi) and V02 max (15.2r0.7 vs 17.1*0.9 ml/kg/ 
mm, p<O.OOl) were also observed. Good correlations were found between GH-induced 
increase in contractile reserve and the increase in V02 max (r=0.62. ~~0.05). ratio IL-IO/ 
TNF-a (r=0.66. p&05) and TGFWNF-a (r=0.56, p<O.O5), as well as the reduction in 
TNF-a levels (r=-0.86, p<O 001). 
Conclusions: GH modulates beneficially cytokine network in DC pts. These immuno- 
modulatory effects may be associated with the improvement in LV contractile perfor- 
mance and exercise capacity of pts wth CHF and DC. 
1106-121 Beneficial Effects of High Doses of Growth Hormone in 
the Optimization of Medical Treatment in 
Decompensated Congestive Heart Failure 
Edimar A. Bocchi, Lidla Z. Moura, Gullherme GuimarBes, Giovanni V. Bellotti, Jose F. 
Ramires, Heart Institute (InCor), University of SBo Paula MedIcal School, SBo Paula, 
Brazil 
Background:Optimizing oral therapy m patients with advanced congestwe heart fail- 
ure(CHF)and cardiac cache& with unstable decompensated and/or dobutamine - 
dependent clinical status is a challenge. 
Methods:We investigated the effects of high doses of recombinant human growth hor- 
mone(GH) in hospitalized 5 patients(pts)with cardiac cachexla and unstable decompen- 
sated CHF(4 dobutamine-dependent) under maximal tolerated medical treatment. Pts 
recewed 6 IU of subcutaneous GH per day. 
Results:(Table)(‘pc.O06),(#p<.Oi) (pre= before GH use, after= after GH use, l&=6-12 
months after GH use),(systemic blood pressure=SBP), (left ventricular ejection frac- 
tion=LVEF)(MUGA).(LV end diastolic diameter=LVEDD (Echo).The NYHA functional 
class improved from IV to I in Ppts, from IV to II in 2, and from IV to 11-111 in l.All pts were 
discharged from the hospitaLIt was possible to optimize long-term CHF treatment with up 
to 50 mg of carvedilol in 4 pts and higher doses of captopril(l50 mg) in all patients.Two 
pts are alive after 40 and 46 months of follow-up.The remaining 3 pts died from a pulmo- 
nary abscess at 9 months, septicemia at 21 months. and unplanned withdrawal of 
carvedilol at 36 months. 
Conclusion:The use of GH in pts with decompensated CHF and cardiac cachexia can 
provide clinical stability without the need for motropic drugs. This could represent a new 
optlon for optimizing long-term CHF life-prolonging oral drug therapy and discharging 
hospitalized patients who are dobutamine-dependent. 
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1106-122 First Demonstration in Humans of Systemic Neutral 
Endopeptidase and Endothelin Converting Enzyme 
Inhibition Using a New Orally Active Dual 
Metalloprotease Inhibitor SLV 306 
Alison Seed Rhoda Kuc, Anthony Davenport, Michael Ashby, Chris Hillier, Hanka De 
Voogd, Hans Essers, John McMurray, University of Glasgow, Glasgow, United Kingdom 
Background: Simultaneous manipulation of several endogenous neurohumoral systems 
IS a new and promising therapeutic approach in hypertension and heart failure. SLV 306, 
through its active metabolite KC 12615, has dual neutral endopeptidase (NEP) and 
endothelin converting enzyme (ECE) inhibiting actiwty in vitro and in experimental ani- 
mals. The aim of this study was to demonstrate these actions in humans. 
Methods: 13 healthy males (mean age 23 years, range 19.38) were studied on 4 occa- 
sions with 1 week apart Subjects were randomised to placebo or one of 3 doses of SLV 
306. A double-blind ascending dose protocol with random insertton of placebo was 
employed. The 3 doses were chosen after a pharmacokinetic study in the same subjects, 
to obtain average plasma concentrations of KC 12615 of 75 (dose 1). 300 (dose 2) and 
1200 (dose 3) nglml. Subjects attended for a 7.hour study involving, in sequence, taking 
a single dose of SLV or placebo, supine rest (3 hours) and infusions of 6 and 12 pmollkgt 
min of big ET-l (20 minutes each). Systolic and diastolic blood pressure (SBP. DBP), 
atria1 natriuretic peptide (ANP), big endothelin-1 (big ET-l) and its cleavage product 
through the action of ECE on big ET-l, ET-l, were measured over 4 hours. 
Results: Mean peak changes in SBP (mmHg)after the second big ET-l infusion 
were:19.4 (placebo),l6.5 (dose 1),14.6 (dose 2), 12.9 (dose 3) (PsO.05). The respective 
changes in DBP were 16.2, 14.3, 12.0 and 11.4 (P<O.O5). The mean, placebo corrected, 
peptide changes over one hour following the second big ET-l infusion for doses 1, 2 and 
3 were; ANP: 7, 11, 15 pg/mL (p<O.Ol), big ET-l: 33,89, 121 fmol/mL (p<O.Ol) and ET- 
1: 0.95, 0.56, 0.02 fmoliml. ET-l levels did not increase as would have been expected 
from a pure NEP-inhibitor, whereas big ET-l levels were increased dose dependently in 
the SLV 306 groups compared to placebo, indicating that the breakdown of big ET-1 was 
inhiblted. SLV 306 was well tolerated. 
Conclusions: This is the first demonstration I” humans of both systemic endothelin con- 
verting enzyme and NEP Inhibition. SLV 306, the lead orally active agent in this new 
class of combined metalloprotease inhibitors, may have therapeutic potential in hyper- 
tension and heart failure. 
1106-123 Hyperkalemia and Impaired Renal Function During 
Treatment With Spironolactone in Patients With 
Congestive Heart Failure: Figures From a Real World 
Scenario 
Marten Svensson, Finn Gustafsson, Soeren Galatius, Dan Atar, Per R. Hildebrandt. 
Frederiksberg University Hospital, Frederiksberg-Copenhagen, Denmark, Aker 
University Hospital, Oslo, Norway 
Backgrounet Treatment wth Spironolactone (SPL) is beneficial in patients with severe 
congestive heart failure (CHF). In the RALES-trial SPL was well tolerated, particularly 
with regard to renal function and serum-@ levels. 
Aim: To investigate whether the reported low frequency of adverse effects during SPL 
treatment in a heart failure population could be confirmed in an unselected heart failure 
outpatient cohort 
Methods: We investigated 125 consecutive patients with CHF recruited from our heart 
failure clinic. Inclusion criteria were LVEF ~45% and treatment with SPL. Mean age was 
72.9 yrs (range 46.5-90.6), 27 4 % were women. NYHA-class distribution was: I: 5.7 %; 
II: 43.9 %; Ill: 46.3 % and IV. 4.1 %. Mean EF was 28 8 +/- 4.5%. Other medications 
included ACE-I in 64.0% and betablockers in 32.6%. Blood tests were performed 
monthly or more frequently If necessary. 
Results At baselme creatinme levels were 117.4+X5 (mean+/-SD; mmolll, normal 
~130) and serum-Q was 4.1+/-0.3 mmolll. The mean follow-up period was 11 months, 
and the cumulative observation period was 73 SPL treatment yrs. 60 pts. were already 
on SPL when admitted to the CHF clinic, with >30% receiving >25 mgld. The remainder 
were Initiated on SPL, with 9% receiving a dose >25 mg/d. During the follow-up period a 
total of 30.0% of the pts. developed hyperkalemia (>5 mmolll), wth 6.3% having serum- 
Kf >6 mmol/l. 53.3% of all patients had an increase of s-creatimne of z-20%, and 23.3% 
increased >50%. These alterations in s-creatinins and serum-@ were not significantly 
more frequent in patients treated with ACE-I or betablokkers or high-dose SPL (>I00 mg/ 
d). 
Conclusion SPL adverse effects (ImpaIred renal function, increase in s-K+) are much 
more prevalent in our elderly CHF patient population than prewously reported. Care 
should be gwen to the continuous monitoring of electrolytes and renal parameters. 
1106-124 Valsartan Produces a Sustained Decrease in Plasma 
Aldosterone Independent of Age, Gender, or Race: 
Results From Val-HeFT 
Roberto LatInI, lnderjit S Anand, Henry Krum, Serge Masson, Monica Salio, Robert 
Glazer, Yue Zhao, Jay Cohn, on behalf of the Val-HeFT Investigators, lstituto Mario 
Negn, Milan, Italy, University of Minnesota, Minneapolis. MN 
Background: Increase m plasma aldosterone in patients (pts) with heart failure (HF) 
may contrlbute to disease progression. Elevations of aldosterone occur frequently during 
effective ACE inhibition (&lsquotdbl;aldosterone escape&rsquotdbl;). We examined the 
effect of valsartan (V). an angiotensin receptor blocker, on aldosterone over time in pt 
subgroups based on gender, age. and race. Methods: Val-HeFT was a randomized, 
double-blind, placebo (P) controlled trial in 5,010 pts with HF, randomized to V or P. 
Aldosterone was measured at baseline and at least one post-baseline tlmepoint (4. 12, 
24 months) in 3,636 pts (male?.: 2,913; females: 723; ~65 yrs: 1,945; ~65 yrs: 1,691; 
blacks- 232; non-blacks: 3,404). Average aldosterone at baseline was 135 pg/mL for V 
